ArticleApplied microbiology and biotechnology2021
Inorganic pellets containing microsclerotia of Metarhizium anisopliae: a new technological platform for the biological control of the cattle tick Rhipicephalus microplus.
Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Defense of locust eggs against Metarhizium anisopliae invasion.Pest management science · 2026Article
- Harnessing environmental microbiological interventions with micro- and macroorganisms for assessing cattle tick management.Scientific reports · 2025Article
- Metarhizium anisopliae and diatomaceous earth for the control of Rhipicephalus microplus ticks: laboratory and field trials.Tropical animal health and production · 2025Article
- Encapsulation of Beauveria bassiana conidia as a new strategy for the biological control of Aedes aegypti larvae.Scientific reports · 2024Article
- Advances in submerged liquid fermentation and formulation of entomopathogenic fungi.Applied microbiology and biotechnology · 2024Review
- Use of a commercial feed supplement based on diatom earth and yeast products on oxidative status and in vitro immune response in buffaloes during peripartum.Journal of animal science · 2024Article
- Microsclerotial pellets of Metarhizium spp.: thermotolerance and bioefficacy against the cattle tick.Applied microbiology and biotechnology · 2023Article
- Production ofJournal of fungi (Basel, Switzerland) · 2022Article
- Production of Microsclerotia byJournal of fungi (Basel, Switzerland) · 2022Article
- A Review of CommercialInsects · 2022Review
- Article
- Diatomaceous Earth for Arthropod Pest Control: Back to the Future.Molecules (Basel, Switzerland) · 2021Review
- Efficacy of focal applications of a mycoinsecticide to control Aedes aegypti in Central Brazil.Applied microbiology and biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study was sought to devise pellets containing inorganic materials and microsclerotia of Metarhizium anisopliae strain IP 119 for biological control of Rhipicephalus microplus, the most economically important tick in Brazilian cattle industry. In addition, we evaluated the storage stability of the pellets, their tolerance to ultraviolet radiation (UV-B), and efficacy against ticks under laboratory conditions. Fungal microsclerotia were produced by liquid culture fermentation and mixed with pre-selected inorganic matrices: vermiculite powder, diatomaceous earth, and colloidal silicon dioxide (78:20:2, w/w/w). The microsclerotial pellets were then prepared by a two-stage process involving extrusion and spheronization. Pellet size averaged 525.53 ± 7.74 μm, with a sphericity index of 0.72 ± 0.01, while biomass constituents did not affect the wet mass properties. Conidial production from microsclerotial pellets upon rehydration ranged from 1.85 × 10
Indexed as
Identifiers
34100979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.